uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of uniQure (NASDAQ:QURE) in a research report report published on Monday morning,Benzinga reports. Chardan Capital currently has a $35.00 price target on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, August 2nd. Guggenheim reaffirmed a “buy” rating and issued a $28.00 price objective on shares of uniQure in a report on Monday, May 12th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of uniQure in a research report on Friday. Mizuho upgraded uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price target on the stock in a research report on Thursday, August 14th. Finally, Cantor Fitzgerald set a $47.00 price target on uniQure in a research note on Wednesday, July 30th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $37.45.

uniQure Price Performance

NASDAQ:QURE opened at $17.43 on Monday. uniQure has a 52 week low of $4.45 and a 52 week high of $19.18. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The firm’s 50-day simple moving average is $15.05 and its 200 day simple moving average is $13.84. The firm has a market cap of $956.38 million, a price-to-earnings ratio of -4.45 and a beta of 0.13.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. As a group, sell-side analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insiders Place Their Bets

In other uniQure news, Director Robert Gut sold 3,336 shares of uniQure stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $48,205.20. Following the transaction, the director owned 56,879 shares in the company, valued at $821,901.55. The trade was a 5.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jack Kaye sold 2,112 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the completion of the transaction, the director directly owned 20,439 shares of the company’s stock, valued at $295,343.55. This trade represents a 9.37% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,144 shares of company stock valued at $322,426 over the last ninety days. 4.79% of the stock is owned by insiders.

Institutional Trading of uniQure

A number of hedge funds have recently added to or reduced their stakes in the stock. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 355.2% during the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock worth $3,550,000 after buying an additional 261,323 shares in the last quarter. Northern Trust Corp grew its position in uniQure by 2.1% during the 4th quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after acquiring an additional 1,923 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in uniQure in the 1st quarter worth about $3,218,000. Woodline Partners LP acquired a new position in uniQure in the 4th quarter worth about $2,484,000. Finally, XTX Topco Ltd raised its position in uniQure by 127.3% in the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 20,720 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.